Zoetis Inc. (NYSE:ZTS) Shares Acquired by WASHINGTON TRUST Co

WASHINGTON TRUST Co lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 0.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,580 shares of the company’s stock after buying an additional 115 shares during the quarter. WASHINGTON TRUST Co’s holdings in Zoetis were worth $11,825,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Mizuho Securities USA LLC grew its stake in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after purchasing an additional 4,829,815 shares during the period. International Assets Investment Management LLC grew its position in Zoetis by 41,235.7% during the third quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after buying an additional 937,700 shares during the period. Assenagon Asset Management S.A. increased its holdings in Zoetis by 296.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 889,444 shares of the company’s stock valued at $144,917,000 after buying an additional 665,331 shares in the last quarter. Nordea Investment Management AB lifted its position in shares of Zoetis by 38.3% during the 4th quarter. Nordea Investment Management AB now owns 2,065,514 shares of the company’s stock valued at $336,266,000 after acquiring an additional 572,511 shares during the period. Finally, Holocene Advisors LP purchased a new stake in shares of Zoetis during the 3rd quarter worth approximately $110,809,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total transaction of $55,804.68. Following the completion of the sale, the executive vice president now owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ZTS shares. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Piper Sandler cut their price target on Zoetis from $210.00 to $200.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Morgan Stanley dropped their target price on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday. Finally, Leerink Partners began coverage on shares of Zoetis in a report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 price target on the stock. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $214.90.

Zoetis Stock Performance

NYSE ZTS opened at $157.54 on Friday. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.53. The business’s 50-day moving average price is $168.89 and its 200 day moving average price is $178.98. The company has a current ratio of 3.69, a quick ratio of 2.27 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $71.08 billion, a PE ratio of 29.61, a price-to-earnings-growth ratio of 2.77 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. On average, research analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be paid a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.27%. Zoetis’s dividend payout ratio is presently 37.59%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.